Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Operating Expenses (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Operating Expenses for 8 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 103.97% year-over-year to -$2.2 million, compared with a TTM value of -$10.5 million through Dec 2025, down 110.37%, and an annual FY2025 reading of -$10.5 million, down 104.22% over the prior year.
  • Operating Expenses was -$2.2 million for Q4 2025 at Arcturus Therapeutics Holdings, up from -$45.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $65.9 million in Q2 2023 and bottomed at -$45.4 million in Q3 2025.
  • Average Operating Expenses over 5 years is $37.2 million, with a median of $49.7 million recorded in 2022.
  • Peak annual rise in Operating Expenses hit 1120.9% in 2025, while the deepest fall reached 186.66% in 2025.
  • Year by year, Operating Expenses stood at $43.4 million in 2021, then decreased by 10.58% to $38.8 million in 2022, then grew by 26.48% to $49.1 million in 2023, then rose by 14.32% to $56.2 million in 2024, then tumbled by 103.97% to -$2.2 million in 2025.
  • Business Quant data shows Operating Expenses for ARCT at -$2.2 million in Q4 2025, -$45.4 million in Q3 2025, and $39.9 million in Q2 2025.